Suppr超能文献

制剂和加工因素对左甲状腺素钠五水合物稳定性的影响。

Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.

机构信息

Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Life Sciences Bldg 64, Silver Spring, Maryland 20993-0002, USA.

出版信息

AAPS PharmSciTech. 2010 Jun;11(2):818-25. doi: 10.1208/s12249-010-9434-8. Epub 2010 May 8.

Abstract

Stability of formulations over shelf-life is critical for having a quality product. Choice of excipients, manufacturing process, storage conditions, and packaging can either mitigate or enhance the degradation of the active pharmaceutical ingredient (API), affecting potency and/or stability. The purpose was to investigate the influence of processing and formulation factors on stability of levothyroxine (API). The API was stored at long-term (25 degrees C/60%RH), accelerated (40 degrees C/75%RH), and low-humidity (25 degrees C/0%RH and 40 degrees C/0%RH) conditions for 28 days. Effect of moisture loss was evaluated by drying it (room temperature, N(2)) and placed at 25 degrees C/0%RH and 40 degrees C/0%RH. The API was incubated with various excipients (based on package insert of marketed tablets) in either 1:1, 1:10, or 1:100 ratios with 5% moisture at 60 degrees C. Commonly used ratios for excipients were used. The equilibrium sorption data was collected on the API and excipients. The API was stable in solid state for the study duration under all conditions for both forms (potency between 90% and 110%). Excipients effect on stability varied and crospovidone, povidone, and sodium laurel sulfate (SLS) caused significant API degradation where deiodination and deamination occurred. Moisture sorption values were different across excipients. Crospovidone and povidone were hygroscopic whereas SLS showed deliquescence at high RH. The transient formulation procedures where temperature might go up or humidity might go down would not have major impact on the API stability. Excipients influence stability and if possible, those three should either be avoided or used in minimum quantity which could provide more stable tablet formulations with minimum potency loss throughout its shelf-life.

摘要

制剂在货架期内的稳定性对于保证产品质量至关重要。辅料的选择、生产工艺、储存条件和包装方式既可以减轻也可以加剧活性药物成分(API)的降解,从而影响其效力和/或稳定性。本研究旨在考察加工和配方因素对左甲状腺素(API)稳定性的影响。将 API 在长期(25°C/60%RH)、加速(40°C/75%RH)和低湿度(25°C/0%RH 和 40°C/0%RH)条件下储存 28 天。通过将 API 干燥(室温,氮气)并在 25°C/0%RH 和 40°C/0%RH 下放置来评估水分损失的影响。将 API 与各种辅料(基于市售片剂的包装说明书)以 1:1、1:10 或 1:100 的比例混合,并在 60°C 下加入 5%水分进行孵育。使用了常用的辅料比例。收集了 API 和辅料的平衡吸附数据。在所有条件下,API 在固态下在研究期间均保持稳定(两种形式的效力在 90%至 110%之间)。辅料对稳定性的影响各不相同,交聚维酮、聚维酮和十二烷基硫酸钠(SLS)导致 API 发生显著降解,出现脱碘和脱氨反应。不同辅料的水分吸附值也不同。交聚维酮和聚维酮具有吸湿性,而 SLS 在高 RH 下显示出潮解现象。制剂的暂态过程中,温度可能会升高或湿度可能会降低,但这不会对 API 稳定性产生重大影响。辅料会影响稳定性,如果可能的话,应尽量避免或使用最小量,以提供更稳定的片剂制剂,在整个货架期内最小程度地降低效力。

相似文献

1
Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.
AAPS PharmSciTech. 2010 Jun;11(2):818-25. doi: 10.1208/s12249-010-9434-8. Epub 2010 May 8.
2
Investigating the Influence of Excipients on the Stability of Levothyroxine Sodium Pentahydrate.
Mol Pharm. 2021 Jul 5;18(7):2683-2693. doi: 10.1021/acs.molpharmaceut.1c00217. Epub 2021 Jun 1.
3
The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets.
Int J Pharm. 2003 Oct 2;264(1-2):35-43. doi: 10.1016/s0378-5173(03)00387-9.
4
Levothyroxine Sodium Pentahydrate Tablets - Formulation Considerations.
J Pharm Sci. 2021 Dec;110(12):3743-3756. doi: 10.1016/j.xphs.2021.08.006. Epub 2021 Aug 10.
5
Partial Dehydration of Levothyroxine Sodium Pentahydrate in a Drug Product Environment: Structural Insights into Stability.
Mol Pharm. 2020 Oct 5;17(10):3915-3929. doi: 10.1021/acs.molpharmaceut.0c00661. Epub 2020 Sep 22.
6
Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
Mol Pharm. 2018 Feb 5;15(2):669-678. doi: 10.1021/acs.molpharmaceut.7b01076. Epub 2018 Jan 19.
7
Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions.
Mol Pharm. 2017 Jan 3;14(1):157-171. doi: 10.1021/acs.molpharmaceut.6b00763. Epub 2016 Dec 7.
8
Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
Eur J Pharm Biopharm. 2021 Jan;158:323-335. doi: 10.1016/j.ejpb.2020.11.025. Epub 2020 Dec 6.
9
Relative Humidity Cycling: Implications on the Stability of Moisture-Sensitive Drugs in Solid Pharmaceutical Products.
Mol Pharm. 2023 Feb 6;20(2):1072-1085. doi: 10.1021/acs.molpharmaceut.2c00812. Epub 2022 Dec 8.
10
Impact of Polymer Type and Relative Humidity on the Long-Term Physical Stability of Amorphous Solid Dispersions.
Mol Pharm. 2017 Dec 4;14(12):4374-4386. doi: 10.1021/acs.molpharmaceut.7b00492. Epub 2017 Nov 7.

引用本文的文献

1
Advancing drug safety and mitigating health concerns: High-resolution mass spectrometry in the levothyroxine case study.
J Pharm Anal. 2024 Sep;14(9):100970. doi: 10.1016/j.jpha.2024.100970. Epub 2024 Mar 28.
2
Ionic Levothyroxine Formulations: Synthesis, Bioavailability, and Cytotoxicity Studies.
Int J Mol Sci. 2023 May 16;24(10):8822. doi: 10.3390/ijms24108822.
3
Co-Crystallization Approach to Enhance the Stability of Moisture-Sensitive Drugs.
Pharmaceutics. 2023 Jan 5;15(1):189. doi: 10.3390/pharmaceutics15010189.
4
Stability and Compatibility Studies of Levothyroxine Sodium in Solid Binary Systems-Instrumental Screening.
Pharmaceutics. 2020 Jan 10;12(1):58. doi: 10.3390/pharmaceutics12010058.
5
Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.
Adv Ther. 2019 Sep;36(Suppl 2):59-71. doi: 10.1007/s12325-019-01079-1. Epub 2019 Sep 4.
6
Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies.
Acta Pharm Sin B. 2016 Jan;6(1):79-92. doi: 10.1016/j.apsb.2015.09.009. Epub 2015 Dec 17.
7
Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.
Molecules. 2015 Dec 3;20(12):21532-48. doi: 10.3390/molecules201219784.
8
Solid-State Characterization and Interconversion of Recrystallized Amodiaquine Dihydrochloride in Aliphatic Monohydric Alcohols.
AAPS PharmSciTech. 2016 Apr;17(2):427-35. doi: 10.1208/s12249-015-0355-4. Epub 2015 Jul 24.
9
Polymeric nucleic acid carriers: current issues and novel design approaches.
J Control Release. 2012 Dec 28;164(3):256-64. doi: 10.1016/j.jconrel.2012.06.036. Epub 2012 Jul 4.
10
Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery.
Biomaterials. 2011 May;32(15):3845-54. doi: 10.1016/j.biomaterials.2011.01.077. Epub 2011 Feb 26.

本文引用的文献

1
Application of melt granulation technology to enhance stability of a moisture sensitive immediate-release drug product.
Int J Pharm. 2009 Oct 20;381(1):56-61. doi: 10.1016/j.ijpharm.2009.05.043. Epub 2009 May 30.
2
Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients.
Int J Pharm. 2008 Aug 6;360(1-2):77-82. doi: 10.1016/j.ijpharm.2008.04.018. Epub 2008 Apr 20.
3
The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets.
Int J Pharm. 2003 Oct 2;264(1-2):35-43. doi: 10.1016/s0378-5173(03)00387-9.
6
Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes.
Adv Drug Deliv Rev. 2001 May 16;48(1):91-114. doi: 10.1016/s0169-409x(01)00100-4.
7
Selection of solid dosage form composition through drug-excipient compatibility testing.
J Pharm Sci. 1999 Jul;88(7):696-704. doi: 10.1021/js980434g.
9
Thermal inactivation of L-thyroxin.
Clin Chem. 1989 Jan;35(1):90-2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验